Want to see CNTX full AI Analyst Report?
Top Page
Context Therapeutics
(NASDAQ:CNTX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.59
▼(-3.93% Downside)
Action:Reiterated
Date:08/01/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and sustained cash burn) and bearish technical positioning (trading well below 50/100/200-day averages). Corporate events are mixed with meaningful positives (clinical/asset-rights progress) but offset by elevated listing-risk from the Nasdaq bid-price notice; valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
Context's very low leverage and still-meaningful equity provide structural financial flexibility to fund R&D and clinical programs without immediate debt pressure. This reduces near-term refinancing risk and supports operational continuity while clinical milestones are pursued.
Negative Factors
No revenue and widening losses
The company has no product revenue and growing net losses, indicating reliance on external capital. Structural negative profitability constrains reinvestment, dilutes shareholder value through future raises, and limits internal funding capacity for multi-year development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Context's very low leverage and still-meaningful equity provide structural financial flexibility to fund R&D and clinical programs without immediate debt pressure. This reduces near-term refinancing risk and supports operational continuity while clinical milestones are pursued.
Read all positive factors
Context Therapeutics (CNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$55.07M
Dividend YieldN/A
Average Volume (3M)3.94M
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS Growth-24.56%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.42
Shares Outstanding91,879,170
10 Day Avg. Volume1,601,550
30 Day Avg. Volume3,936,235
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.67Price Target Upside828.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.39
Revenue Forecast (FY)N/A
Context Therapeutics Business Overview & Revenue Model
Company Description
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediat...
How the Company Makes Money
null...
Context Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -40.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -40.18M | -36.11M | -26.71M | -23.95M | -14.87M | -10.53M |
| Net Income | -40.23M | -36.12M | -26.73M | -23.96M | -14.84M | -10.46M |
Balance Sheet | ||||||
| Total Assets | 58.86M | 68.49M | 98.13M | 16.06M | 37.97M | 51.31M |
| Cash, Cash Equivalents and Short-Term Investments | 54.53M | 66.00M | 94.43M | 14.45M | 35.50M | 49.64M |
| Total Debt | 282.42K | 112.06K | 219.38K | 0.00 | 55.08K | 0.00 |
| Total Liabilities | 6.66M | 8.02M | 2.86M | 4.19M | 3.21M | 3.03M |
| Stockholders Equity | 52.20M | 60.47M | 95.27M | 11.87M | 34.76M | 48.27M |
Cash Flow | ||||||
| Free Cash Flow | -32.82M | -26.42M | -29.31M | -21.05M | -14.09M | -9.05M |
| Operating Cash Flow | -32.79M | -26.39M | -14.56M | -21.05M | -13.55M | -8.80M |
| Investing Cash Flow | -2.04M | -2.03M | -14.76M | 0.00 | -536.84K | -250.00K |
| Financing Cash Flow | 0.00 | -15.27K | 109.29M | 0.00 | -102.07K | 58.39M |
Context Therapeutics Technical Analysis
Neutral
0.61
Price Trends
1.08
Negative
1.81
Negative
1.72
Negative
Market Momentum
-0.10
Negative
37.46
Neutral
51.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Neutral. The current price of 0.61 is below the 20-day moving average (MA) of 0.61, below the 50-day MA of 1.08, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 37.46 is Neutral, neither overbought nor oversold. The STOCH value of 51.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CNTX.
Context Therapeutics Risk Analysis
Context Therapeutics disclosed 61 risk factors in its most recent earnings report. Context Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Context Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $22.87M | -0.19 | 1823.49% | ― | ― | 35.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $177.70M | -7.95 | -48.20% | ― | 7336.90% | 49.64% | |
49 Neutral | $207.07M | -2.29 | -79.63% | ― | -100.00% | -1124.16% | |
43 Neutral | $55.07M | -1.41 | -59.95% | ― | ― | -24.56% | |
42 Neutral | $13.46M | -1.70 | -74.58% | ― | ― | 33.15% |
* Healthcare Sector Average
CNTX
Context Therapeutics
0.62
-0.08
-11.29%
WHWK
Whitehawk Therapeutics
4.14
2.37
133.90%
QNCX
Quince Therapeutics
27.41
-310.59
-91.89%
ADAG
Adagene
3.64
1.74
91.68%
ANEB
Anebulo Pharmaceuticals
0.32
-2.32
-87.88%
Context Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Context Therapeutics Receives Nasdaq Minimum Bid Price Notice
Negative
Jul 31, 2026
On July 29, 2026, Context Therapeutics Inc. received a notification from Nasdaq that its common stock was no longer in compliance with the Minimum Bid Price Rule, having closed below $1.00 per share for 30 consecutive business days. The notice doe...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Context Therapeutics Shareholders Approve Stock Increase and Directors
Positive
Jun 26, 2026
On June 24, 2026, Context Therapeutics Inc. held its Annual Meeting of Stockholders, with a quorum of approximately 79.27% of the 91,879,177 shares outstanding as of the April 27, 2026 record date, and elected seven directors to serve until the 20...
Business Operations and StrategyProduct-Related Announcements
Context Therapeutics Highlights Positive CTIM-76 Phase 1 Data
Positive
Jun 15, 2026
On June 15, 2026, Context Therapeutics posted an updated corporate presentation outlining its strategy to build a leading pipeline of next-generation T cell engager bispecific antibodies for solid tumors. The presentation detailed three main progr...
Business Operations and Strategy
Context Therapeutics Secures Full Rights to Antibody Assets
Positive
May 18, 2026
On May 14, 2026, Context Therapeutics amended its 2024 exclusive license agreement with BioAtla for certain antibody assets, including its Nectin-4 x CD3 T cell engager CT-202. In exchange for a $4.5 million payment within five business days of th...
Business Operations and StrategyLegal ProceedingsShareholder Meetings
Context Therapeutics settles governance lawsuit with mootness fee
Negative
May 1, 2026
On March 11, 2026, the Delaware Court of Chancery approved a consent judgment in a stockholder class action against Context Therapeutics, determining that charter provisions establishing three-year director terms and removal of directors only for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.